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Cuprophan reuse and intradialytic changes of lung diffusion capacity
and arterial blood gasses. The changes in arterial blood gas, pulmonary
function tests, leukocyte counts and complement activition were eval-
uated during first use and subsequent reuse of cuprophan dialyzers. The
dialysate buffer was bicarbonate. Reuse of cuprophan dialyzers signif-
icantly attenuated the fall in leukocyte counts and the rise in C3a des Arg
seen during first use dialysis. First use dialysis also caused a drop in
arterial paO2 from 93.0 12.4 mm Hg to a nadir of 82.8 12.6 mm Hg
at 60 minutes (P < 0.01). Pa02 levels did not change when reused
dialyzers were employed (93.7 12.2 before dialysis and 96.4 15.2
mm Hg at 60 minutes, P > 0.05). Intradialytic paO2 curves obtained
during first use and reuse were significantly different by variance
analysis (P < 0.001). There was also a significant decline in lung
diffusion capacity (DLCO, from 30.70 8.89 to 23.77 7.76
mI/mm. mm Hg, P < 0.01) and transfer factor (KCO, from 6.07 1.97
to 5.65 2.13 mI/mm mm Hg, P < 0.01), during first use at one hour
after initiation of dialysis. This decrease was entirely prevented during
reuse, (P < 0.001 vs. first use by variance analysis). Percentual changes
in leukocyte counts and C3a des Arg concentration on one hand, and in
paO2, DLCO and KCO on the other were significantly correlated to
each other. Other factors with a possible influence on intradialytic
pulmonary function such as ultrafiltration volume, dialysate buffer
composition, evolution of intradialytic blood pH and cardiac output,
were all identical under both experimental conditions. These data
indicate that there is a direct relationship between intradialytic comple-
ment activation and leukocyte pulmonary sequestration, and pulmo-
nary dysfunction.
The development of hypoxemia and pulmonary dysfunction
during hemodialysis has been attributed in part to intrapulmon-
ary leukocyte entrapment, resulting from activation of the
complement system [1—31. These events have been shown to be
most pronounced when cuprophan membranes are used and are
significantly attenuated by reuse of cuprophan dialyzers or by
the use of synthetic membranes, such as polyacrylonitrile or
polymethylmethacrylate [4—8].
Previous studies demonstrated that such synthetic mem-
branes cause less intradialytic hypoxemia than cuprophan [91,
suggesting a relationship between complement activation and
intradialytic pulmonary dysfunction. Other studies failed to
detect such a relationship [10—13].
Received for publication October 14, 1986
and in revised form February 17, 1987
© 1987 by the International Society of Nephrology
The comparative evaluation of new and reused dialyzers and
their corresponding effects on intradialytic pulmonary dysfunc-
tion seemingly would represent a useful model for the study of
the pathophysiologic role of complement activation in this
setting, since this would make it possible to evaluate the same
dialyzer (new and reused) on the same patient with the only
variable being the extent of complement activation and
leukopenia from the intrapulmonary sequestration of activated
neutrophils.
Intradialytic pulmonary dysfunction during reuse of dialyzers
has only rarely been studied; the few studies which addressed
this tissue pointed to a similar degree of intradialytic hypoxemia
both with first use and reused cuprophan dialyzers [11, 14].
The present study was therefore undertaken to compare in
the same 12 patients changes in blood gas as well as specific and
sensitive parameters of pulmonary function and diffusion ca-
pacity, together with leukocyte counts and parameters of com-
plement activity, during first use and third reuse of the same
cuprophan dialyzers.
Methods
Patients
This study was undertaken in 12 stable, chronic dialysis
patients, six males and six females, treated by chronic dialysis
for 30.3 29.3 months (mean SD, range 3 to 87 months). The
mean age was 53.7 7.8 years (mean SD, range 24 to 68
years). The cause of renal failure was chronic glomerulonephri-
tis in six, chronic pyelo-interstitial nephritis in four, and
nephro-angiosclerosis and polycystic kidney disease each in
one patient. Patients with active infectious problems, cardio-
vascular diseases and/or on steroid treatment were excluded
from the study. None of the patients under study was known to
have chronic heart failure or active lung disease. A pre-study
chest X-ray revealed no abnormalities in any patient. Four of
them were smokers; smoking habits were not changed during
the course of the study.
All dialysis sessions during the study were performed with a
1 m2 capillary cuprophan filter (Tecno 50 5, Bellco, Mirandola,
Italy). All patients had previously been treated with different
dialyzer types and had not been on reuse. The patients were not
aware whether they were on a first use or a reused dialyzer.
The patients were treated three times for four hours weekly,
with a single—needle dialysis system (Beilco BL 760) on a single
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Table 1. Basic pulmonary function data
Unit
Obtained
result
Expected
value %°
Vital capacity (VC) liter 3,44 0.75 4.14 0.66 84 18C
Total lung capacity liter 5.58 1.14 6.24 0.87 90 17
Forced expiratory volume in
I sec (FEY1) liter 2.59 0.78 3.08 0.51 84 21"
FEV,/VC % 74.5 10.1 77.9 1.3 95 12
Airway resistance cm H20. sec/liter 3.13 1.46 0.05 — 2.20
Diffusion capacity mI/mm. mm Hg 31.24 7.36 27.00 3.24 116 25
Transfer coefficient mi/mm mm Hg 6.07 1.59 5.68 0.34 106 27
% indicates percentual difference between the obtained results and the expected values
"P < 0.05 obtained vs. expected
P < 0.01 obtained vs. expected
pass system with bicarbonate dialy sate, containing 31 mEq/liter
of bicarbonate. Blood and dialysate flow averaged 300 and 500
ml/min, respectively.
Each patient was evaluated twice, one week apart. The initial
treatment was with a first use dialyzer followed by the reuse of
the same dialyzer for one week. At the third reuse, the same
evaluations were performed as during the initial control exper-
iment.
The reuse procedure was performed automatically with the
ADR 22® Device (Texas Medical Instruments, Houston,
Texas, USA). Hydrogen peroxide was used as a rinsing prod-
uct, and 4% formaldehyde as a sterilant, as described elsewhere
[15].
Before the start of the study, pulmonary function was eval-
uated on a non-dialysis day. The following parameters were
obtained: vital capacity (VC), total lung capacity (TLC), forced
expiratory volume in one second (FEy,, FEV,/VC, airway
resistance (RAW), lung diffusion capacity (DLCO) and transfer
coefficient (KCO). The latter two factors were corrected for
blood hemoglobin. The expected values were derived from the
study by Quanjer [15].
During each experimental dialysis, alveolar ventilation (VA),
DLCO and KCO were measured predialysis and at 15, 60 and
240 minutes of dialysis. Volumes were measured using a closed
circuit, water—sealed circuit spirometer (Expirograph, Godart,
Netherlands). Each volume represents the mean of three mea-
surements. DLCO was measured using the single breath
method with an apnea time of 10 seconds (Transfer, Morgan,
UK). KCO was calculated by dividing the diffusion capacity by
the alveolar volume.
The following dialysis parameters were studied at regular
intervals during both experimental dialysis sessions: body
weight (measured by a bed scale monitor), ultrafiltration vol-
ume, mean arterial blood pressure and heart rate [16]. Cardiac
output was measured by a non-invasive Doppler method,
before dialysis and after 15, 60 and 240 minutes, as described
earlier [17, 181.
Blood for blood gas analysis was obtained before dialysis and
after 3, 6, 9, 15, 30, 60 and 240 minutes. Blood was extracted
anaerobically from the arterial blood line into ice—chilled
heparinized syringes, and was assayed immediately thereafter
by means of a Corning 168 Analyzer (Corning, Midfield, Mas-
sachusetts, USA) for pH, arterial carbon dioxide tension
(paCO2), bicarbonate concentration, base excess and oxygen
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tension (paO2). Based on the obtained blood gasses, the arterial
alveolar P02 difference (a-ADO2) was calculated as previously
described [19].
In addition, peripheral arterialized blood was sampled in
heparinized tubes for the determination of red and white blood
cell, platelet and eosinophil counts. These samples were ob-
tained prior to the start of dialysis, and at 15, 60 and 240 minutes
of the dialysis procedure.
Complement activity was evaluated by radioimmunological
determination of the plasma concentration of C3a des Arg
(Upjohn Company, Kalamazoo, Michigan) [20]. For this assay,
blood was sampled at 0, 15, 60 and 240 minutes from afferent
and efferent blood lines in EDTA tubes, centrifuged, separated
immediately and stored at —70°C until processing.
Data are expressed as means standard deviation. Statistical
comparisons towards control values were obtained by means of
Wilcoxon's test for paired values. The evolution of intradialytic
lung function and of arterial oxygen tension during first use and
reuse were compared to each other by three way analysis of
variance. Correlation regression analysis was performed by
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Fig. 1. Volume of ultrafiltration (A), heart rate (B), meanarterial
blood pressure (C) and cardiac output (D) before and after 15, 60 and
240 minutes of first use (full line) and third reuse (dotted line)
cuprophan dialysis. There were no significant differences.
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Table 2. Evolution of leukocyte counts (cells/mm3)
0 mm 15 mm 60 mm 240 mm
Total leukocytes
First use 6680 1850 2130 1020"
(68.l%Y'
5820 l020
(—12.9%)
7570 l650
(+ 13.3%)
Reuse 6830 1540 5750 I650
(—15.8%)
6440 1650
(—5.7%)
6750 1660
(—l.2%)
a P < 0.05 vs. pre-dialysis
b P < 0.01 vs. pre-dialysis
P < 0.01 vs. first use
"values between brackets indicate the percentage changes from pre-dialysis values
significant difference in the number of the total leucocytes
present at 15 minutes of dialysis (P < 0.01).
Figure 2 illustrates the intradialytic evolution of C3a des Arg
levels, both during first use and third reuse. Samples collected
from the afferent and the efferent blood lines are studied. There
is a marked rise in C3a des Arg levels in the afferent blood lines,
up to a maximum of 4.33 0.75 xg/ml, and up to 6.21 0.88
xg/ml at the efferent side at 15 minutes. Although there is still a
significant rise in C3a des Arg levels after the third reuse, the
changes are largely attenuated, with a maximum level of C3a des
Arg of 0.58 0.10 and 0.91 0.10 g/ml at the afferent and
efferent side, respectively.
Figure 3 illustrates the intradialytic changes in paO2 using
new or reused cuprophan membranes. With first use cuprophan
dialyzers, there is a significant decline in paO2 from the 15th up
to the 60th minute of dialysis. This fall in paO2 is absent in the
case of reused hemodialyzers. Overall, paO2 was always lower
during first use, compared to reuse. Comparison of the obtained
paO2 values during first use and reuse by variance analysis
revealed overall a highly significant difference (P < 0.001).
At 15 minutes, there was a significant correlation between
percent changes in paO2 on one hand and in leukocyte counts
on the other [i paO2 = (0.16 x leukocytes) —1.43; N 24, r
= 0.50, P < 0.011. Similarly, a correlation was found between
percent changes in paO2 and in C3a des Arg concentrations [z
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Fig. 2. Evolution of C3a des Arg levels during first use (left) and reuse
dialysis (right) before dialysis and at 15, 60 and 240 minutes. Samples
were collected from afferent (full lines) and efferent blood lines (dotted
lines). * P < 0.05 and **p < 0.01 vs. before dialysis. The marked rise
in C3a des Arg during first use is largely attenuated during reuse.
calculating the Spearman index. Statistical significance was
accepted for P < 0.05.
Results
Table 1 illustrates pulmonary function data, obtained on the
patients under study on a non-dialysis day. The vital capacity,
total lung capacity, forced expiratory volume in one sec (FEy1)
and FEV1/VC were somewhat lower, whereas the airway
resistance, diffusion capacity and transfer coefficient were
higher than the expected value. Significant differences were
only observed for the vital capacity, and for FEY1.
In Figure 1, the net ultrafiltration volume and the change of
the mean arterial blood pressure and heart rate during dialysis
are illustrated together with the intradialytic cardiac output for
both first use and reuse dialysis. Only minor and statistically
non-significant changes occur in heart rate, mean arterial blood
pressure and cardiac output. There are no significant differ-
ences in these parameters between new and reused dialyzers.
Table 2 summarizes the evolution of the total leukocyte
counts during the experiments. There is a fall of total leukocyte
count by 68% after 15 minutes of first use dialysis, followed by
a rebound at the end of dialysis. Both phenomena are largely
and significantly attenuated when reused dialyzers are used,
although there still remains a slight but significant decrease in
leukocyte counts after 15 minutes of dialysis (z —16%, P < 0.01
vs. pre-dialysis counts).
When the first use and reuse data are compared, there is a
Fig. 3. Evolution of arterial oxygen tension (paO2) before and after 3,
6, 9, 15, 30, 60 and 240 minutes of first use (full line) and third reuse
(dotted line) cuprophan dialysis. ** P < 0.01 vs. pre-dialysis; both
curves were significantly different by variance analysis (P < 0.001).
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Table 3. Blood gas analysis parameters
0 mm 3 mm 6 mm 9 mm 15 mm 30 mm 60 mm 240 mm
pH
First use 7.38 7.39 7.40a 7.40 7.40a 7.40a 7.40a 748b
Reuse 7.37 7.38 7.38 7.37 7.38 7.39 7.40 7.46"
paCO2 mm Hg
First use 34.7 34.9 35.1 33.7 35.5 36.1 37.6 37.3
Reuse 32.5 33.2 33.1 33.4 33.7 34.6 34.9 33.9
Bicarbonate mEqiliter
First use 20.7 20.9 21.5 20.8 21.6" 224b 235b 28.0"
Reuse 18.7 I9.9 19.6 19.4 19.9 20.9a 21.8a 24.5"
Base excess mEqiliter
First use —3.2 —2.9 —2.3 —2.7 56b
Reuse —5.2 —3.7 44 3,9a —2.8" +2.!"
P < 0.05 pre-dialysis
b P < 0.01 pre-dialysis
paO2 = (0.01 x 1 C3a des
0.0 11.
The evolution of the remaining blood gas parameters is
illustrated in Table 3. Although there was a progressive
intradialytic increase of pH, bicarbonate concentration and
base excess without major changes in paCO2, there are no
significant differences between the two experimental condi-
tions.
Based on the observed paO2 and paCO2 values, it was
possible to calculate the alveolar—arterial oxygenation gradient
(A-aDO2). With first use cuprophan, A-aDO2 increased from a
control value of 16.2 11.3 to a maximum of 22.9 13.6 at 15
and 22.4 12.8 mm Hg at 30 and 60 minutes (P < 0.01 vs.
before first use dialysis). During reuse, A-aDO2 decreased from
13.3 10.2 mm Hg (before dialysis) to 8.0 4.3 (at 60 mm).
Values obtained during first use and reuse were again signifi-
cantly different by variance analysis.
The evolution of the pulmonary function parameters during
dialysis is illustrated in Figure 4. There is a net decline versus
control in DLCO during the entire dialysis session with first—use
cuprophan dialyzers, with a maximum decline of 23% at 60
minutes. Although there is still a slight fall in DLCO during
reuse, all intradialytic values are not significantly different from
pre-dialysis control, whereas they differ significantly from the
results obtained with first use dialysis by variance analysis (P <
0.001). The differences between first use and reuse are at least
as pronounced when KCO is evaluated; this parameter also
decreases at first use and remains unaltered at reuse, the
difference between both procedures being highly significant (P
<0.001).
Percent changes in DLCO were correlated significantly with
changes in leukocyte counts and C3a des Arg concentration [
DLCO = (0.32 x leukocytes) + 2.73; N = 24, r = 0.63, P <
0.001; DLCO (—0.01 X C3a des Arg) — 0.38; N = 24, r
0.68, P < 0.001]. A similar highly significant correlation was
seen for percentual changes in KCO [ KCO = (0.27 X
Arg) —0.58; N = 24, r = 0.50, P < leukocytes) + 1.05; N 24, r 0.68, P < 0.001; KCO =
(—0.01 X C3a des Arg) —4.76; N = 24, r = 0.64, P <0.001].
There were no changes in alveolar ventilation (VA) except for
an 8% decrease compared to pre-dialysis values at the end of
reuse dialysis (P < 0.05). There were no significant differences
between first use and reuse by variance analysis for this
parameter (P > 0.05).
Discussion
The present study indicates that intradialytic hypoxemia and
a decrease in lung diffusion capacity are seen using bicarbonate
dialysate with first—use cuprophan dialyzers. The extent of
these changes is significantly attenuated when these dialyzers
are reused on the same patients. Intradialytic complement
activation and leukopenia are also attenuated with dialyzer
reuse, confirming previous data [6-8].
It should be stressed that the observed changes in pulmonary
function were not related to a decrease in alveolar ventilation;
the presence of such a fall in alveolar ventilation early in
dialysis has entirely been attributed to the use of acetate as a
dialysate buffer [21], since acetate provokes a wash—out of CO2
from the blood and a decrease of respiratory drive, whereas
bicarbonate does not. Therefore, the fall of paO2 in the present
study in patients on bicarbonate dialysis should be attributed to
an impairment of the other constituant of pulmonary function,
pulmonary diffusive capacity. This supposition is confirmed by
the finding of both a decrease in lung diffusion capacity and
transfer factor in parallel with the observed hypoxemia when
bicarbonate and first use cuprophan are combined to each
other.
The present data thus emphasize the pathophysiological
importance of complement activation and leukocyte activation
as well as their pulmonary sequestration in dialysis patients, in
view of the remarkable parallelism between the rise in comple-
ment activity and the fall in lung diffusion capacity; they
confirm the formerly suggested [9] but often debated [10—13]
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from dialysate imposed hypoventilation [9]. By demonstrating a
significantly higher change in the alveolar arterial oxygen
gradient (A-aDO2) when nonbiocompatible complement—acti-
vating cuprophan filters were used, compared to the more
biocompatible AN 69 dialyzers, and by finding equivalent
changes in paO2, these authors collected convincing arguments
in favor of a dual mechanism for intradialytic pulmonary
dysfunction, one dialysate buffer and one membrane related.
The present data are a confirmation of their suggestion of
dialyzer membrane related, pulmonary function changes during
dialysis. Apart from a divergent evolution of paO2 and A-aDO2
with first use and reuse, in parallel with other findings [9], we
were able to demonstrate differences in the evolution of the lung
diffusion capacity and transfer factor as well, which is a more
direct way to confirm changes in the gas diffusion through the
pulmonary interstitium.
It could be argued that the standard deviation of DLCO and
KCO is rather high on reuse, so that a 23% prevention of both
parameters dropping by reuse should be interpreted with care.
It should be stressed, however, that an improvement of the
evolution of DLCO and KCO was seen with reuse in all patients
but one. The patients were used as their own control so that
within group variation is relatively irrelevant. Furthermore, the
finding of a significant correlation between percent changes in
leukocyte counts and complement activity on one hand, and
paO2, DLCO and KCO on the other, further supports the
suggestion that intradialytic pulmonary function, complement
activity and leukocytosis are interrelated.
The present data are seemingly in contradiction with the
results presented by Hakim and Lowrie, who found a fall in
paO2, during dialysis both with non-biocompatible cuprophan
dialyzers as well as with biocompatible AN 69 dialyzers [5].
These data were however obtained during acetate hemodialy-
sis, and it is conceivable that the fall in paO2 with both dialyzers
found by these authors can thus be explained by the dialysate
buffer composition. Irrespective of this dialysate related factor,
Hakim et al found paO2 to be significantly higher with AN 69
than with cuprophan, stressing again the importance of mem-
brane composition in the evolution of intradialytic pulmonary
function.
This study contradicts two earlier studies on reuse and lung
function, where no significant differences in arterial oxygen
tension between first use and reuse dialysis were found [11, 14].
The latter results are in disagreement with the concept of a
relationship between intradialytic pulmonary function and com-
plement activity. It should be stressed that these results are to
be interpreted with the necessary care. First, in both studies
acetate dialysate was used and this factor may cause
intradialytic hypoxemia. Second, arterial oxygen tension was
the only assessed parameter of pulmonary function. A particu-
lar level of paO2 reflects, however, several influences (respira-
tory drive, lung diffusion capacity, paCO2, dialysate buffer
composition), so that this paO2 can be supposed to be a rather
weak parameter of intradialytic pulmonary function. It was
therefore decided in the present study to use bicarbonate
buffered dialysate and to evaluate a-ADO2, DLCO and KCO as
more adequate parameters of lung diffusion. KCO is an even
more sensitive indicator than DLCO since it does not take into
account alveolar ventilation.
There are, apart from changes in pulmonary diffusion, mul-
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Fig. 4. Alveolar volume (VA - A), lung diffusion capacity (DLCO - B)
and transfer factor (KCO - C) before and after 15, 60 and 240 minutes
of first use (full line) and third reuse (dotted line) cuprophan dialysis.
** P < 0.01 vs. pre-dialysis; both DLCO and KCO curves were
significantly different by variance analysis (P < 0.001); for VA no
significant difference was found.
relationship between complement activation and a decrease in
intradialytic lung diffusion capacity. These two phenomena are
linked to each other by a number of complex mechanisms [3],
complement activation being followed by diverse biological
actions such as leukocyte sequestration in the lungs, and the
release of vasoactive compounds from these activated leuko-
cytes, resulting in pulmonary vasoconstriction, edema and
possible bronchospasm.
Apart from this, complement factors may also act directly on
the pulmonary vasculature to induce pulmonary hypertension
and hypoxemia, as demonstrated recently in animal experi-
ments [22, 23].
De Backer et al showed already in 1982 that intradialytic
hypoxemia could be attributed to a second mechanism, apart
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tiple other fctors that may influence the intradialytic evolution
of arterial oxygen tension and pulmonary function as well, such
as ultrafiltration volume [24], dialysate buffer composition [9,
25], the evolution of intradialytic blood pH and bicarbonate
concentration [261, or differences in cardiac output [27]. Many
of these factors have remained uncontrolled in former studies.
To minimize all these biases, in the present study all patients
were treated similarly once with first use and once with reuse on
the same day of the week by the same dialysate, containing 31
mEq/liter of bicarbonate; it was also shown that there were no
differences in ultrafiltered volume, blood gas analyses and
cardiac output obtained at different moments of dialysis be-
tween the two experimental settings (Fig. 1, Table 3).
It should be stressed that observed pulmonary function
changes with first—use cuprophan dialyzers may be related to
hemodynamic instability and other complications in the short
term [22, 28], and to a higher complication rate and mortality in
the long term [29, 301. It therefore appears important to
minimize complement activation and its consequences during
dialysis, especially in view of the fact that quite often patients
may remain on dialysis for many years.
In brief, reuse of cuprophan dialyzers was associated with an
attenuation of the leukopenia and the complement activation
currently seen with first use. Concomitantly, and in contrast
with previous reports, dialysis hypoxemia was prevented,
which could mainly be attributed to the maintenance of a
normal lung diffusion capacity. These data confirm a relation-
ship between complement activation and intradialytic pulmo-
nary dysfunction.
Reprint requests to R. Vanholder, M.D., Nephrology Department,
University Hospital, De Pintelaan 185, B-9000 Gent, Belgium.
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